What are the pharmacokinetic and pharmacodynamic properties of morphine?

Pharmacokinetics and Pharmacodynamics of Morphine

Morphine exhibits poor oral bioavailability (20-30%) with significant interindividual variability, undergoes hepatic glucuronidation to active (M6G) and inactive (M3G) metabolites, and acts primarily as a mu-opioid receptor agonist with an elimination half-life of 1.5-2 hours. 1, 2

Pharmacokinetics

Absorption and Bioavailability

• Oral bioavailability is only 20-30% due to extensive first-pass metabolism, contributing to unpredictable onset and marked interindividual variability in dose requirements 1
• Peak plasma concentrations after subcutaneous injection occur within 15-30 minutes, providing more rapid onset than oral administration 1
• The oral-to-parenteral potency ratio is 1:2 to 1:3 (meaning 20-30 mg oral morphine equals approximately 10 mg subcutaneous/IV) 1, 3

Distribution

• Volume of distribution: 1.0-4.7 L/kg after parenteral administration 2
• Low protein binding (36%) and muscle tissue binding (54%) 2
• Crosses the blood-brain barrier, though plasma concentrations remain higher than CSF levels 2

Metabolism

• Primary pathway: hepatic glucuronidation via UGT2B7 to two major metabolites 2, 4:
  • Morphine-6-glucuronide (M6G): pharmacologically active, 7.8 times more potent than morphine but with delayed effect-site equilibration (4.25 hours vs 0.33 hours for morphine) 5
  • Morphine-3-glucuronide (M3G): pharmacologically inactive, may exhibit mild opioid antagonist properties 5
• The M3G/M6G ratio remains relatively stable within individual patients but varies between patients 6

Elimination

• Elimination half-life: 1.5-2 hours in normal subjects 2
• Total plasma clearance: 0.9-1.2 L/kg/h with considerable interindividual variation 2
• Renal excretion: 2-12% unchanged morphine; metabolites primarily excreted renally (90% urine, 10% feces) 2

Critical Caveat - Renal Impairment

Active metabolites accumulate significantly in renal failure, particularly M6G and M3G, contributing to toxicity 1, 5. This represents a major clinical pitfall requiring dose reduction or alternative opioid selection in patients with compromised renal function.

Pharmacodynamics

Mechanism of Action

• Full mu-opioid receptor agonist with relative selectivity for mu receptors, though can interact with other opioid receptors at higher doses 2
• Produces analgesia through CNS opiate receptors distributed throughout brain and spinal cord 2

Central Nervous System Effects

• Primary effect: analgesia, along with anxiolysis, euphoria, and sedation 2
• Respiratory depression via direct effect on brainstem respiratory centers 2
• Cough suppression through direct medullary effects 2
• Miosis (pupillary constriction) even in darkness 2
• Effect-site equilibration half-life (ke0) approximately 0.003 min⁻¹ for miotic effects 7

Gastrointestinal Effects

• Decreased gastric, biliary, and pancreatic secretions 2
• Reduced GI motility with increased tone leading to constipation (the main persistent adverse effect requiring prophylactic laxatives) 1
• Increased biliary tract pressure from sphincter of Oddi spasm 2
• Potential urinary retention from bladder sphincter spasm 2

Cardiovascular Effects

• Minimal effects at therapeutic doses 2
• Peripheral vasodilation potentially causing orthostatic hypotension 2
• Histamine release may contribute to hypotension, pruritus, flushing 2

Endocrine Effects

• Inhibits ACTH, cortisol, and luteinizing hormone secretion 2
• Stimulates prolactin and growth hormone secretion 2

Pharmacodynamic Variability

Morphine concentrations are NOT predictive of analgesic response, especially in opioid-tolerant patients 2. The minimum effective concentration varies widely based on:

• Prior opioid exposure
• Age
• General medical condition
• Individual pain characteristics 1

Time Course Considerations

• Transient side effects (drowsiness, dizziness, nausea/vomiting) occur in up to two-thirds of patients at initiation but typically resolve within days 1
• Cognitive and psychomotor impairment is minimal in patients on stable doses 1
• M6G contribution increases over time with peak effect-site concentration occurring 4.25 hours after morphine bolus, while M3G antagonism may emerge after 1-2 days 5

Formulation-Specific Kinetics

• Normal-release morphine: duration 4 hours 1
• Modified-release 12-hour formulations: no substantial differences in duration or potency between various products 1
• Modified-release 24-hour formulations: pharmacokinetic differences exist but without clinically significant impact on efficacy 1

Clinical Implications

The combination of poor oral bioavailability, active metabolite formation (particularly M6G), and significant interindividual variability necessitates careful dose titration. Normal-release formulations are essential for initial titration with rescue dosing every 4 hours, followed by conversion to modified-release for maintenance 1. The delayed contribution of M6G and potential antagonism from M3G accumulation explain why some patients may require opioid rotation after 1-2 days of therapy 5.